A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...
Lantheus (NASDAQ:LNTH) reported what management described as a strong start to 2026, citing solid performance from its three core commercial products—PYLARIFY, Neuraceq® and DEFINITY—and progress on multiple regulatory and pipeline milestones during the first quarter.
On the call, CEO and Executive
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 1.2% year on ...
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) will be reporting results this Thursday before the bell. Here’s what to look for. Lantheus beat a...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-...
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...
What a fantastic six months it’s been for Lantheus. Shares of the company have skyrocketed 57%, hitting $83.14. This run-up might have investors contemplatin...
Let’s dig into the relative performance of Lantheus (NASDAQ:LNTH) and its peers as we unravel the now-completed Q4 medical devices & supplies - imaging, diag...
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 4% year on year to $406.8 million. On the other hand, the company’s full-year revenue guidance of $1.43 billion at the midpoint came in 4.6% below analysts’ estimates. Its non-GAAP profit of $1.67 per share was 42.9% above analysts’ consensus estimates.
